The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,050,373 | -6,145,305 |
| Accounts receivable | - | 134,599 |
| Non-cash stock-based compensation | 157,692 | 490,840 |
| Depreciation and amortization | 5,303 | 10,241 |
| Change in carrying amount of right-of-use asset | 41,701 | 92,732 |
| Prepaid expenses and other assets | -369,325 | 13,208 |
| Accounts payable, accrued liabilities and other liabilities | 163,331 | -285,850 |
| Deferred revenue | 521,899 | - |
| Operating lease liability | -46,674 | -104,918 |
| Net cash used in operating activities | -1,703,197 | -6,090,067 |
| Acquisitions of property and equipment | 2,899 | - |
| Net cash used in investing activities | -2,899 | - |
| Effect of exchange rate changes on cash and cash equivalents | 9,071 | -10,034 |
| Net change in cash and cash equivalents | -1,697,025 | -6,100,101 |
| Cash and cash equivalents at beginning of period | 40,359,738 | - |
| Cash and cash equivalents at end of period | 32,562,612 | - |
MEDICINOVA INC (MNOV)
MEDICINOVA INC (MNOV)